Abstract
In the first part of this review studies are considered in which pre- or post-training peripheral or intracerebroventricular administrations of competitive or noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonists were carried out in a variety of animal species tested in different experimental conditions, in order to investigate the effects of these drugs on acquisition and memory processes. In particular, post-training treatments, which are known to affect memory consolidation, ruling out the possible aspecific effects linked to the pre-training administrations, show that the NMDA receptor antagonists impair memory in animals tested in various tasks. Memory impairments are also evident when the NMDA antagonists (in particular AP5) are injected into different brain structures, including amygdala and hippocampus. In a second part of this review some recent studies are considered showing the existence of: a) cholinergic-glutamatergic interactions; b) interactions between NMDA receptors and opioid system, and c) interactions between NMDA receptor antagonists (MK-801) and cocaine, in the modulation of memory processes of laboratory animals. The results of some studies showing the involvement of glutamatergic mechanisms in Alzheimers disease are finally reported, and the therapeutic efficacy of glutamatergic drugs in the treatment of this disease is considered.
Keywords: NMDA Receptors, glutamatergic drugs, 2-amino-5-phosphonopentanoic acid, intrahippocampal infusions, MK-801
Current Drug Targets
Title: NMDA Receptors and Learning and Memory Processes
Volume: 2 Issue: 3
Author(s): C. Castellano, V. Cestari and A. Ciamei
Affiliation:
Keywords: NMDA Receptors, glutamatergic drugs, 2-amino-5-phosphonopentanoic acid, intrahippocampal infusions, MK-801
Abstract: In the first part of this review studies are considered in which pre- or post-training peripheral or intracerebroventricular administrations of competitive or noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonists were carried out in a variety of animal species tested in different experimental conditions, in order to investigate the effects of these drugs on acquisition and memory processes. In particular, post-training treatments, which are known to affect memory consolidation, ruling out the possible aspecific effects linked to the pre-training administrations, show that the NMDA receptor antagonists impair memory in animals tested in various tasks. Memory impairments are also evident when the NMDA antagonists (in particular AP5) are injected into different brain structures, including amygdala and hippocampus. In a second part of this review some recent studies are considered showing the existence of: a) cholinergic-glutamatergic interactions; b) interactions between NMDA receptors and opioid system, and c) interactions between NMDA receptor antagonists (MK-801) and cocaine, in the modulation of memory processes of laboratory animals. The results of some studies showing the involvement of glutamatergic mechanisms in Alzheimers disease are finally reported, and the therapeutic efficacy of glutamatergic drugs in the treatment of this disease is considered.
Export Options
About this article
Cite this article as:
Castellano C., Cestari V. and Ciamei A., NMDA Receptors and Learning and Memory Processes, Current Drug Targets 2001; 2 (3) . https://dx.doi.org/10.2174/1389450013348515
DOI https://dx.doi.org/10.2174/1389450013348515 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Established and In-trial GPCR Families in Clinical Trials: A Review for Target Selection
Current Drug Targets Increased Epileptiform EEG Activity and Decreased Seizure Threshold in Arctic APP Transgenic Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Therapeutic Potential of Metabotropic Glutamate Receptor Modulators
Current Neuropharmacology CNS Drug Delivery Systems: Novel Approaches
Recent Patents on Drug Delivery & Formulation HIV-1 Tat-Induced Changes in Synaptically-Driven Network Activity Adapt During Prolonged Exposure
Current HIV Research On Various Metrics Used for Validation of Predictive QSAR Models with Applications in Virtual Screening and Focused Library Design
Combinatorial Chemistry & High Throughput Screening Does Phosphodiesterase 11A (PDE11A) Hold Promise as a Future Therapeutic Target?
Current Pharmaceutical Design Why Anticancer Nanomedicine Needs Sugars?
Current Medicinal Chemistry Oxidative Stress in the Molecular Mechanism of Pathogenesis at Different Diseased States of Organism in Clinics and Experiment
Current Drug Targets - Inflammation & Allergy Could Hippocampal Neurogenesis be a Future Drug Target for Treating Temporal Lobe Epilepsy?
CNS & Neurological Disorders - Drug Targets Physiopathological Roles of P2X Receptors in the Central Nervous System
Current Medicinal Chemistry Blood-Brain Barrier P450 Enzymes and Multidrug Transporters in Drug Resistance: A Synergistic Role in Neurological Diseases
Current Drug Metabolism Recombinant Expression, Functional Characterization of Two Scorpion Venom Toxins with Three Disulfide Bridges from the Chinese Scorpion Buthus martensii Karsch
Protein & Peptide Letters Understanding the Potential Role and Delivery Approaches of Nitric Oxide in Chronic Wound Healing Management
Current Pharmaceutical Design Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging
Current Medicinal Chemistry Editorial: Novel Perspectives in the Treatment of Epilepsy
Current Pharmaceutical Design Patent Selections
Recent Patents on Computer Science Update on the Evaluation and Management of Brief Resolved Unexplained Events (Previously Apparent Life-Threatening Events)
Reviews on Recent Clinical Trials Pyrrolizidine Alkaloids and their Biological Properties from Indian Heliotropium Species
Current Bioactive Compounds SiRNA Mediated Gene Silencing: Hurdles, Strategies and Applications
Pharmaceutical Nanotechnology